ferumoxtran-10: Clinical Trials

4 trials of ferumoxtran-10, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 4 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 3, Terminated 1
Phase 12Completed 2

Follow ferumoxtran-10: new trials by email Literature Review of ferumoxtran-10 trials Research Report on ferumoxtran-10

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
fludeoxyglucose F 18, positron emission tomography, computed tomography - Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)3842007-09-012019-07-23
Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer
ferumoxtran-10, magnetic resonance imaging, sentinel lymph node biopsy - Breast Cancer
Phase 2CompletedVirginia Commonwealth University32005-09-012010-05-03
Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide
MRI contrast agent Combidex (ferumoxtran-10) - Uterine Neoplasms, Cervix Neoplasms
Phase 1 / Phase 2CompletedUniversity Health Network, Toronto612004-04-012022-10-07
Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation
Ferumoxtran-10 (Combidex), Neurosurgery - Brain Neoplasms
Phase 2TerminatedOHSU Knight Cancer Institute1162000-08-012022-12-21

Conditions studied

Uterine Cervical Neoplasms (2)  ·  Brain Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Breast Neoplasms, Male (1)  ·  Endometrial Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)  ·  Uterine Neoplasms (1)

Sponsors

National Cancer Institute (NCI) (1)  ·  OHSU Knight Cancer Institute (1)  ·  University Health Network, Toronto (1)  ·  Virginia Commonwealth University (1)

Countries

United States (3)  ·  Canada (2)  ·  Japan (1)  ·  South Korea (1)

Top investigators

Edward A Neuwelt, MD (1)  ·  Karen A. Kurdziel, MD (1)  ·  Michael Milosevic, MD (1)  ·  Mostafa Atri (1)

NIH funding

P30CA016059 (1), R01NS034608 (1), U10CA027469 (1), U10CA180868 (1)